
IndraLab
Statements
Hydroxychloroquine inhibits endocytosis. 21 / 21
|
5
16
eidos
"Some drugs from the primary investigations that are used for COVID-19 are protease inhibitor lopinavir / ritonavir , nucleoside analogs , neuraminidase inhibitors , remdesivir , umifenovir ( arbidol ) , tenofovir disoproxil ( TDF ) , lamivudine ( 3TC ) and hydroxychloroquine , which blocks virus entry and endocytosis ( Lu , 2020 ) ( Figure 1 ) ."
eidos
"The investigational drugs which are being explored to target different steps of SARS-CoV-2 lifecycle in humans including inhibition of entry of virus into the target cell by inhibition of angiotensin-converting enzyme-2 receptor and transmembrane protease serine-2 ( TMPRSS2 ) by Olumiant ( baricitinib ) 7 and camostat mesylate , 8 respectively ; inhibition of the viral entry by inhibition of the membrane fusion and endocytosis by chloroquine or hydroxychloroquine 9 and umifenovir ( arbidol ) 10 ; inhibition of viral replication by protease inhibitors such as lopinavir 11 and darunavir ; and blockade of viral ribonucleic acid ( RNA ) synthesis by remdesivir , 12 ribavirin , 13 and favipravir ."
| PMC
reach
"Antivirals such as camostat mesylate (inhibitor of TMPRSS2), chloroquine/hydroxychloroquine (inhibitor of endocytosis), lopinavir/darunavir (inhibitor of 3‑chymotrypsin-like protease) or ribavirin, remdesivir, favipiravir (inhibitor of RNA-dependent RNA polymerase), or prednisolone should be restricted to controlled or randomized trials such as the worldwide WHO-cosponsored Solidarity Trial (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)."
eidos
"6 The investigational drugs which are being explored to target different steps of SARS-CoV-2 lifecycle in humans including inhibition of entry of virus into the target cell by inhibition of angiotensin-converting enzyme-2 receptor and transmembrane protease serine-2 ( TMPRSS2 ) by Olumiant ( baricitinib ) 7 and camostat mesylate , 8 respectively ; inhibition of the viral entry by inhibition of the membrane fusion and endocytosis by chloroquine or hydroxychloroquine 9 and umifenovir ( arbidol ) 10 ; inhibition of viral replication by protease inhibitors such as lopinavir 11 and darunavir ; and blockade of viral ribonucleic acid ( RNA ) synthesis by remdesivir , 12 ribavirin , 13 and favipravir ."
| PMC
reach
"Antivirals such as camostat mesylate (inhibitor of TMPRSS2), chloroquine/ hydroxychloroquine (inhibitor of endocytosis), lopinavir/darunavir (inhibitor of 3-chymotrypsin-like protease) or ribavirin, remdesivir, favipiravir (inhibitor of RNA-dependent RNA polymerase), or prednisolone should be restricted to controlled or randomized trials such as the worldwide WHO-cosponsored Solidarity Trial (https://www."
reach
"Moreover, Chloroquine and Hydroxychloroquine prevent viral entry and endocytosis, and also play the role of potential immunomodulatory agents.The immune system components react to SARS-CoV-2 mainly related to the inter-individual variation in COVID-19 severity, whereas genes linked with the binding affinity to the ACE2 cell receptor and the viral entry at the early stages of infection, considerably determine thevariable COVID-19 severity and different susceptibility to SARS-CoV-2 infection."
reach
"Antivirals such as camostat mesylate (inhibitor of TMPRSS2), chloroquine and hydroxychloroquine (inhibitor of endocytosis), lopinavir and darunavir (inhibitor of 3-chymotrypsin-like protease) or ribavirin, remdesivir, favipiravir (inhibitor of RNA dependent RNA polymerase), or prednisolone should be restricted to controlled or randomized trials such as the worldwide WHO cosponsored Solidarity Trial (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)."